Haihe Pharmaceutical: wholly-owned subsidiary has obtained the approval notice for the raw material of Minocycline Hydrochloride.

HaiZheng Pharmaceutical announced that its wholly-owned subsidiary, HaiZheng Pharmaceutical Nantong Co., Ltd., has received the "Chemical raw material drug market application approval notice" issued by the National Medical Products Administration for the approval of the raw material drug of Minocycline Hydrochloride. The global sales volume in 2024 is estimated to be approximately 35,648.65 kilograms, with domestic sales volume of around 7,914.5 kilograms. From January to March 2025, the global sales volume is estimated to be around 8,572.46 kilograms, with domestic sales volume of around 2,092.66 kilograms. The company has invested approximately 19.21 million RMB in the research and development project of this drug.